Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Update

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 500,700 shares, a growth of 161.3% from the January 31st total of 191,600 shares. Based on an average daily volume of 3,200,000 shares, the short-interest ratio is currently 0.2 days. Currently, 6.4% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Cumberland Pharmaceuticals in a report on Friday, February 14th. They issued a “hold” rating on the stock.

Institutional Trading of Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP grew its stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,649 shares of the specialty pharmaceutical company’s stock after acquiring an additional 18,271 shares during the quarter. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent SEC filing. 15.51% of the stock is currently owned by institutional investors.

Cumberland Pharmaceuticals Price Performance

CPIX stock traded down $0.11 during midday trading on Friday, reaching $4.86. The stock had a trading volume of 62,369 shares, compared to its average volume of 2,460,966. The company’s fifty day simple moving average is $3.39 and its 200 day simple moving average is $2.06. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The company has a market cap of $68.24 million, a price-to-earnings ratio of -6.31 and a beta of 0.12. Cumberland Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $7.19.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.